Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Colleague Insights
Grand Rounds
Conferences
Video Expert Opinion
Living Resources
Sign in
Join now
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
Nekesha Oliphant MD
Nekesha Oliphant MD Advisory Board
See All Experts
story of the week
Published in Primary Care and
2 other channels

Journal Scan / Research · October 09, 2020

Dapagliflozin in Patients With Chronic Kidney Disease

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Steven Coca DO, MS

Peter Lin MD, CCFP

The New England Journal of Medicine
Dapagliflozin in Patients With Chronic Kidney Disease
N. Engl. J. Med 2020 Sep 24;[EPub Ahead of Print], HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, FF Hou, JFE Mann, JJV McMurray, M Lindberg, P Rossing, CD Sjöström, RD Toto, AM Langkilde, DC Wheeler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated